Non Small Cell Lung Cancer - pembrolizumab - ER expression

Association details:

Biomarker:	ER expression
Cancer:	Non Small Cell Lung Cancer
Drug:	Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

EACR 2021

Title:

Gender and estrogens as key factors in the response to immunotherapy in non-small cell lung cancer

Published date:

05/28/2021

Excerpt:

We analyzed a panel of 80 genes with NanoString technology in 42 patients treated with Pembrolizumab to identify the most significantly genes associated with better outcome....ESR1 gene, encoding for ERα, was positively associated with response to Pembrolizumab in patients....Our data demonstrate that 17-β-estradiol/ERα status predicts the response to Pembrolizumab in NSCLC...